Adjuvant immunotherapy in resected non-small cell lung cancer harboring oncogenic driver alterations beyond EGFR and ALK: results from a retrospective analysis.
Real-world data on adjuvant immunotherapy for rare NSCLC driver mutations fills evidence gaps for treatment decisions.
This retrospective analysis addresses a clinical evidence gap for adjuvant immunotherapy in resected NSCLC harboring driver alterations beyond EGFR and ALK (e.g., KRAS, RET, MET), populations typically excluded from or underrepresented in pivotal adjuvant trials. Initial efficacy signals from real-world data can help guide treatment decisions for these patients.
What the study was
- Study design
- Retrospective cohort analysis
- Population
- Resected NSCLC patients with non-EGFR/ALK oncogenic driver alterations (KRAS, RET, MET, ROS1, NTRK, etc.) receiving adjuvant immunotherapy
- Category
- Treatment Innovation
- Maturity
- Exploratory
- Journal
- Clinical & translational oncology
Why it surfaced
Adjuvant ICI in non-EGFR/ALK NSCLC driver populations fills an important evidence gap. This population is underserved by current trial evidence.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.